ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

Income Statement

Follow revenue through to earnings.

Revenue

$84.28M

FY 2025 · Annual

-5.5% YoY

Operating Income

-$179.45M

FY 2025 · Annual

Net Income

-$171.30M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.51M1.32M30K89.15M84.28M
Cost of Revenue213K17.12M020.56M20.42M
Gross Profit5.29M(15.8M)30K68.59M63.86M
Gross Margin96.1%-1200.9%100.0%76.9%75.8%
Research & Development20.27M18.38M20.27M19.58M13.18M
Selling, General & Admin4.69M18.66M47.28M0230.12M
Operating Expenses24.75M19.71M67.55M71.68M243.3M
Depreciation & Amortization213K319K73K79K1.37M
EBITDA(19.92M)(34.36M)(54.29M)8.37M(167.41M)
EBITDA Margin-361.9%-2611.2%-180973.3%9.4%-198.6%
Operating Income(19.45M)(35.52M)(67.52M)(3.08M)(179.45M)
Operating Margin-353.3%-2698.8%-225066.7%-3.5%-212.9%
Interest Income800K00010.67M
Interest Expense106K0002.6M
Other Income / Expenses(789K)834K13.16M11.37M8.07M
Income Before Tax(20.24M)(34.68M)(54.37M)8.29M(171.38M)
Pre-Tax Margin-367.7%-2635.4%-181216.7%9.3%-203.3%
Income Tax Expense000288K(80K)
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Net Margin-367.7%-2635.4%-181216.7%9.0%-203.3%
EPS (Basic)(0.70)(0.87)(0.57)0.08(1.74)
EPS (Diluted)(0.70)(0.87)(0.57)0.08(1.74)
Weighted Avg Shares28.87M39.96M95.22M96.94M98.57M
Weighted Avg Shares (Diluted)28.87M39.96M95.22M102.39M98.57M

SPRY Earnings Waterfall · TTM

NASDAQ:SPRY · Revenue to Net Income

Key Ratios

EPS$-2.01
Gross Margin76.0%
Net Margin-214.3%
P/E Ratio-6.2
P/S Ratio53.9

Analysis

$99.0M of revenue converted into -$198.0M of net income for the selected period. Gross margin is 76.0% and net margin is -214.3%, showing how much revenue survives after costs and taxes. EPS is $-2.01, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
3Initial statement of beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipOct 5, 2026

How much revenue does SPRY generate?

ARS Pharmaceuticals, Inc. (SPRY) reported $84.28M of revenue in fiscal 2025.

Is SPRY profitable?

ARS Pharmaceuticals, Inc. (SPRY) reported -$171.30M of net income, with a net margin of -203.3%.